4.7 Article

Metformin and fluoxetine improve depressive-like behavior in a murine model of Parkinsons disease through the modulation of neuroinflammation, neurogenesis and neuroplasticity

期刊

INTERNATIONAL IMMUNOPHARMACOLOGY
卷 102, 期 -, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.intimp.2021.108415

关键词

Parkinsons disease; Rotenone; Depression; Metformin; Fluoxetine

资金

  1. Research Excellence Program - Instituto Aggeu Magalhaes (IAM-PROEP) [400208/2019-9]
  2. Knowledge Generation Program of the Fundacao Oswaldo Cruz (FIOCRUZ) [VPPCB-007-FIO-18-2-17]
  3. Institute of Science and Technology of Neuroimmunomodulation (INCT-NIM) [465489/20141]
  4. National Council for Scientific and Technological Development (CNPq) [301777/2012-8]
  5. Coordination for the Improvement of Higher Education Personnel-Brazil (CAPES) [001]

向作者/读者索取更多资源

This study evaluated the effects of metformin and fluoxetine in an experimental model of Parkinson's disease. The results showed that metformin and fluoxetine can prevent depressive symptoms, improve motor impairment, and have anti-inflammatory, neurogenic, and neuroplasticity-inducing effects. The combined treatment of these two drugs can enhance these effects.
Thereabout 30-40% of patients with Parkinson's Disease (PD) also have depression contributing to the loss of quality of life. Among the patients who treat depression, about 50% do not show significant improvement due to the limited efficacy of the treatment. So far, there are no effective disease-modifying treatments that can impede its progression. The current clinical approach is based on symptom management. Nonetheless, the reuse of drugs with excellent safety profiles represents an attractive alternative strateg y for treating of different clinical aspects of PD. In this study, we evaluated the effects of metformin separately and associated with fluoxetine on depressive like-behavior and motor alterations in experimental Parkinson's disease. C57BL6 mice were induced with rotenone (2.5 mg/kg/day) for 20 days and treated with metformin (200 mg/kg/day) and fluoxetine (10 mg/ kg/day) from the 5th day of induction. The animals were submitted to Sucrose Preference, Tail Suspension, and rotarod tests. Hippocampus, prefrontal cortex, and substantia nigra were dissected for molecular and morpho-logical analysis. Metformin and fluoxetine prevented depressive-like behavior and improved motor impairment and increased TH nigral positive cells. Metformin and fluoxetine also reduced IBA-1 and GFAP positive cells in the hippocampus. Moreover, metformin reduced the phospho-NF-kB, IL-1 beta in the prefrontal corte x and iNOS levels in the hippocampus. Both metformin and fluoxetine increased neurogenesis by increasing KI67, but only the combined treatment increased neuronal survival by NeuN positive cells in the hippocampus. In addition, fluoxetine reduced cell death, decreasing caspase-3 and PARP-1 levels. Lastly, metformin potentiated the effect of fluoxetine on neuroplasticity by increasing BDNF positive cells. Metformin has antidepressant and anti-parkinsonian potential due to anti-inflammatory neurogenic, and neuroplasticity-inducin g effects when com-bined with fluoxetine.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据